Federal contract for as much as $30M moves Columbus biotech on path to FDA approval

invirsa-logo

A Columbus biopharmaceutical startup has won up to a $30 million federal contract to develop a treatment for a chemical warfare attack – which also helps in common conditions like pink eye.

Click here to read the complete story.

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Originally published November 2, 2020.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: